rticosteroids. infrequently, signs and symptoms of glucocorticosteroid insufficiency may occur requiring supplemental systemic corticosteroids. for information on systemic supplementation, see prescribing information for those products. pediatric patients may be more susceptible to systemic toxicity from equivalent doses due to their larger skin surface to body mass ratios. (see precautions: pediatric use .) if irritation develops, luxiq should be discontinued and appropriate therapy instituted. allergic contact dermatitis with corticosteroids is usually diagnosed by observing a failure to heal rather than noting a clinical exacerbation, as with most topical products not containing corticosteroids. such an observation should be corroborated with appropriate diagnostic patch testing. in the presence of dermatological infections, the use of an appropriate antifungal or antibacterial agent should be instituted. if a favorable response does not occur promptly, use of luxiq should be discontinued until the infection has been adequately controlled.

ptions; hypopigmentation; perioral dermatitis; allergic contact dermatitis; secondary infection; skin atrophy; striae; and miliaria. systemic absorption of topical corticosteroids has produced reversible hypothalamic-pituitary-adrenal (hpa) axis suppression, manifestations of cushing’s syndrome, hyperglycemia, and glucosuria in some patients.

pilledema. administration of topical corticosteroids to children should be limited to the least amount compatible with an effective therapeutic regimen. chronic corticosteroid therapy may interfere with the growth and development of children.

crease percutaneous absorption. the use of pharmacodynamic endpoints for assessing the systemic exposure of topical corticosteroids is necessary due to the fact that circulating levels are well below the level of detection. once absorbed through the skin, topical corticosteroids are handled through pharmacokinetic pathways similar to systemically administered corticosteroids. they are metabolized, primarily in the liver, and are then excreted by the kidneys. in addition, some corticosteroids and their metabolites are also excreted in the bile.

s contained in luxiq? • are you pregnant? planning on becoming pregnant while using luxiq? or are you breastfeeding? • do you think you have an infection on your scalp? how to apply luxiq turn the can upside down and dispense a small amount of luxiq onto a clean saucer or other cool, clean surface. do not dispense directly onto hands, as foam will begin to melt immediately upon contact with warm skin. pick up small amounts of foam with fingers and gently massage into affected area until foam disappears. repeat until entire affected scalp area is treated. apply twice daily, once in the morning and once at night. use sparingly–only enough to cover the affected areas. gently massage the foam in until it is absorbed and allow the areas to dry naturally. when applying to the scalp, move the hair away so that the foam can be applied directly to each affected area. wash your hands immediately after applying luxiq, and discard any unused dispensed medication. do not wash or rinse the treated areas immediately after applying luxiq. • do not use this medication for any condition other than the one for which it was prescribed. • luxiq is for external use only. • keep the foam away from your eyes, as it will sting. if the foam gets into your eyes, rinse well with cold water. if the stinging continues, contact your doctor immediately. what you should know about luxiq: what to do if you miss an application if you forget to apply luxiq at the scheduled time, use it as soon as you remember, and then go back to your regular schedule. if you remember at or about the time of your next daily application, apply that dose and continue with your normal application schedule. if you miss several doses, tell your doctor at your next appointment. about side effects as with all medications, there may be some side effects. the most frequent side effects associated with the use of luxiq include mild burning, stinging, or itching at the site of application. these side effects typically disappear shortly after application. let your doctor know if you notice any of the following: • any unusual effects that you do not understand. • affected areas that do not seem to be healing after several weeks of using the foam. important safety notes • the treated areas should not be bandaged or covered unless directed by your doctor. • keep this and all medicines out of the reach of children. • store the can at controlled room temperature 20° to 25°c (68° to 77°f) and protect it from direct sunlight, as this is a pressurized container. • keep away from and do not spray near fire, open flame, or direct heat--this product is flammable. do not smoke while using or holding the can. keep the can away from all sources of ignition. do not pierce or burn the can, and never throw the can in a fire, even if empty. • when you have finished your treatment, dispose of the can safely. a completely empty can is recyclable. • do not use the foam after the expiration date shown on the bottom of the can. • do not give luxiq to anyone else. your doctor has prescribed this medicine for your use only. for additional information visit www.luxiq.com questions: call mylan at 1-877-446-3679 (1-877-4-info-rx). side effects should be reported to this number. luxiq is a registered trademark of stiefel laboratories, inc., a gsk company, exclusively licensed to the mylan companies ©2018 delcor asset corporation, a mylan company manufactured for: mylan pharmaceuticals inc. morgantown, wv 26505 u.s.a. manufactured by: dpt laboratories, ltd. san antonio, tx 78215 u.s.a. 140989-0418 revised: 4/2018 dpt:betafon:r1 patient information figure 1 patient information figure 2 patient information figure 3 patient information figure 4